ImmunityBio soars after FDA seeks details for wider use of bladder cancer drug

Shares of drug developer ImmunityBio IBRX.O rise 31.3% to $7.22

Co says it is preparing to resubmit its application seeking U.S. approval for the use of its bladder cancer drug, Anktiva, in a broader group of patients, following new guidance from the FDA

Co says FDA asked for more information but no new trials; plans resubmission within 30 days

Long-term data showed nearly all patients on Anktiva along with BCG survived at least three years and over 80% kept their bladder, avoiding surgery - IBRX

BCG is a decades-old bladder cancer treatment made from a weakened bacterium that helps the immune system attack cancer cells

Anktiva is already cleared in U.S., UK, Saudi Arabia and conditionally in EU for related uses - IBRX

As of last close, stock down ~23% over the past year